DirectMeds makes two claims that stand out in this market, and both deserve scrutiny rather than applause. Claim one: $147/month flat - for either semaglutide or tirzepatide, at every dose. Claim two: you can take it as weekly injections or as needle-free sublingual drops. The first claim is unusual economics; the second is unusual medicine. Let's check both.
The economics first: pricing tirzepatide at the same rate as semaglutide is genuinely rare - everywhere else in our ranking, tirzepatide carries a $40-$100 premium. And dose-flat pricing kills the industry's habit of quoting starter-dose rates that climb as you titrate. Nothing about either practice signals corner-cutting; both signal a company competing on transparency.
